Sheetal Desai, MD, leads the discussion on the recent approval of guselkumab, an IL-23 inhibitor, for the treatment of adults with active psoriatic arthritis.
Evaluation and Management of Real-World Cases of Psoriatic Arthritis
Advertisement
Advertisement
Trending on HCPLive
1
How Does the FDA Approval of Risankizumab Impact Pediatric Psoriasis and PsA? With Amy Paller, MD
2
Counseling Patients On Exa-cel Gene Therapy Journey, With Haydar Frangoul, MD, MS
3
New Nonsteroidal Options Are Reshaping Pediatric Atopic Dermatitis Care
4
Q&A: How Is Risankizumab’s FDA Approval Changing the Psoriatic Disease Landscape?
5